ArticleCHEST pulmonary2025
Supplemental Oxygen Payments and Equipment Utilization in a Low-Income Population With Interstitial Lung Disease or COPD.
Article in CHEST pulmonary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Supplemental oxygen induced cardiovascular pathophysiology in an end-of-life care model in mice.Physiological reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Supplemental oxygen is often prescribed to patients with interstitial lung disease (ILD) and COPD, and oxygen services are often paid through Medicare or Medicaid benefits. The specific costs to Centers for Medicaid and Medicare Services for oxygen therapy in these diseases have not been fully described. Research Question: What are the estimated payments by Medicare and Medicaid for supplemental oxygen therapy, and do differences in oxygen equipment utilization or other factors impact these payments in low-income individuals with ILD or COPD? Study Design and Methods: We reviewed claims data for years 2016 to 2020 for Pennsylvania residents with ILD or COPD who were dually eligible for Medicaid and Medicare and enrolled in traditional fee-for-service Medicare. A multilevel mixed-effects generalized linear model was used to identify variables associated with annual oxygen payments made by Medicare or Medicaid. Results: Compared with COPD, a greater proportion of paid claims in ILD were for oxygen services (40% vs 22%) and for high flow oxygen (4.2% vs 2.2%); however, ILD represented the minority of paid oxygen claims (5.2%). The median payment for oxygen was similar at $64.53 (interquartile range, $35.04-$94.56) for ILD and $65.84 (interquartile range, $33.63-$96.70) for COPD. Most claims (≥ 94%) were for stationary concentrators. Liquid devices and stationary gas were the least used equipment. Lower payments were associated with living in a competitive bidding area and with markers of advanced age and worse health status. Higher payments were associated with living in nonmetropolitan areas, having equipment delivering high oxygen flow, and receiving liquid oxygen or a portable oxygen concentrator in addition to a stationary concentrator. Interpretation: Oxygen payments and equipment utilization were similar between patients with ILD and COPD who were dually eligible for Medicare and Medicaid services; however, liquid oxygen claims were rare even among patients requiring high flow.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.